Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study

TKIs long-term treatment in CML may lead to persistent adverse events (AEs) that can promote relevant morbidity and mortality. Consequently, TKIs dose reduction is often used to prevent AEs. However, data on its impact on successful treatment-free remission (TFR) are quite scarce. We conducted a ret...

Descripción completa

Detalles Bibliográficos
Autores principales: Iurlo, A., Cattaneo, D., Consonni, D., Castagnetti, F., Miggiano, M. C., Binotto, G., Bonifacio, M., Rege-Cambrin, G., Tiribelli, M., Lunghi, F., Gozzini, A., Pregno, P., Abruzzese, E., Capodanno, I., Bucelli, C., Pizzuti, M., Artuso, S., Iezza, M., Scalzulli, E., La Barba, G., Maggi, A., Russo, S., Elena, C., Scortechini, A. R., Tafuri, A., Latagliata, R., Caocci, G., Bocchia, M., Galimberti, S., Luciano, L., Fava, C., Foà, R., Saglio, G., Rosti, G., Breccia, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076530/
https://www.ncbi.nlm.nih.gov/pubmed/37033642
http://dx.doi.org/10.3389/fphar.2023.1154377

Ejemplares similares

Ejemplares similares